October 30, 2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Dear Sir/Madam,

Sub: Results Presentation for the period ended September 30, 2026
Ref: Dai-ichi Karkaria Limited (Scrip Code 526821)

Please find enclosed herewith the Results Presentation of the Company for the period ended September 30, 2026, the same will be placed on the website of the Company i.e. https://www.dai-ichiindia.com/investor/

For **DAI-ICHI KARKARIA LIMITED**

ANKIT PARIMAL SHAH

Digitally signed by ANKIT PARIMAL SHAH
Date: 2026.10.30 19:15:24 +05'30'

Ankit Shah
Company Secretary and Compliance officer

Encl: as above

DAI-ICHI
Specialty Chemicals

Q2 FY26-27
COMPANY PRESENTATION

ABOUT US

- Dai-ichi India commenced production in 1963, in technical collaboration with Dai-ichi Kogyo Seiyaku based in Japan.
- We develop and manufacture high-performance speciality chemicals for various industrial applications.
- We market innovative products, providing custom solutions tailored to our client's needs.
- Sustainability and innovation are key factors in all our business operations.

OUR STRENGTHS

Research & Development

We work towards creating products and processes that are clean, reflecting the integrity of our manufacturing process, with minimum use of hazardous chemicals and efficient chemical synthesis.

Customers have partnered with us to resolve specific performance issues, challenging our R&D team to find a cost effective solution.

Quality Control

Our batch-to-batch consistencies are maintained by rigorous, regular and complete testing at every stage.

We conform to all relevant health, safety, environmental, national, and international standards.

Innovation

We work with a focus on product design, process efficiency and environmental health & safety.

By integrating new technologies and sustainable practices, we aim to reduce our environmental impact while enhancing product performance.

OUR MILESTONES

1963

Commenced production in Pimpri, Pune, in technical collaboration with Dai-ichi Kogyo Seiyaku of Japan

1967

Developed the first demulsifier in India for ONGC

1980

Developed the first PPD in India

1981

Technical collaboration with Matsumoto Yushi-Seiyaku of Japan for sizing agents & Spin Finishes

1991

Established a JV with Baker Petrolite for the manufacture of oil field chemicals

1995

Dai-ichi Karkaria India listed on BSE; Invested in flocculants plant in Kurkumbh; Set up a pharmaceutical facility in Hyderabad, concluded in 2015

2005

JV is created for pharma products with Inogent, in collaboration with GVK Biosciences

2008

Acquired 40% stake of Baker Production Services (UK), making it a wholly owned subsidiary of Dai-ichi

2009

Formed a JV with Champion Technologies (now ChampionX), specifically for the Indian oil field upstream chemical sector

2018

Commissioning of our new plant in Dahej, for the manufacture of Alkoxylates and Oilfield chemicals

2022

Oilfield plant commissioned December 2022 with enhanced capacities

2026

Ethoxylation capacity expansion; commissioned new oilfield reactors to modernise production line.

MANUFACTURING CAPABILITIES



INDUSTRIES CATERED TO

Agrochemicals

Construction Chemicals

Home & Personal Care

Oilfield Chemicals

Paints, Pigments & Coatings

Rayon Additives

Sizing Chemicals

Textile Auxiliaries

Flocculants for Paper, Sugar & Mining Industry

Water & Environment

Q2 FY26-27 RESULTS

MANAGEMENT NOTE

We are pleased to report continued progress in the second quarter of FY 2026-27. Revenue for Q2 was Rs. 54.11 crore, representing growth of approximately 26% over the corresponding quarter of the previous year. For the first half, revenue of Rs. 111.95 crore was approximately 36% higher than the corresponding period of the previous year, and profit after tax for the first half was Rs. 5.74 crore, compared with Rs. 1.85 crore in the corresponding period of the previous year.

Growth during the quarter was broad based across our business segments. Oilfield Chemicals remained our largest segment, supported by steady demand in international markets and the commercialisation of new products. Home & Personal Care continued its strong performance, with quarterly revenue nearly three times that of the corresponding quarter of the previous year, supported by sustained export demand.

Paints & Coatings and Textiles recovered well from the first quarter, in line with the improvement we had indicated. Agrochemicals followed its usual seasonal pattern after a strong first quarter, with new product development progressing well.

Margins during the quarter were moderated by higher raw material and freight costs. Renewed geopolitical tensions in the Middle East drove a sharp rise in crude oil prices through the quarter, which increased the cost of key petrochemical feedstocks, including ethylene oxide. The disruption to regional shipping routes, together with reduced vessel capacity and port congestion, also led to a significant increase in ocean freight rates on our export shipments. We continue to work closely with our customers on pricing and to optimise our sourcing and logistics to manage these pressures.

On the manufacturing front, our Dahej facility achieved record production in its ethoxylation operations during the quarter, and the capacity expansion commissioned in Q1 is now being utilised. We also continued to strengthen our safety and sustainability practices, including progress on our Responsible Care programme.

We remain focused on building on the momentum of the first half, deepening customer relationships across our segments, and driving sustainable, profitable growth for our shareholders.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDING 30/09/26

Amount in Rs Lakhs

Particulars	Quarter ended			Half year ended		Year ended
	30-09-2026 Unaudited	30-06-2026 Unaudited	30-09-2025 Unaudited	30-09-2026 Unaudited	30-09-2025 Unaudited	31-03-2026 Audited
Revenue from Operations	5,411	5,784	4,279	11,195	8,224	16,130
Cost of material consumed & changes in inventory	3,811	3,731	2,810	7,542	5,326	10,682
Employee Benefits Expenses	702	714	648	1,416	1,297	2,566
Other Expenses	801	740	642	1,541	1,294	2,536
Operating Earning Before Interest, Tax, Depreciation	**97**	**599**	**179**	**696**	**307**	**346**
EBITDA Margin	2%	10%	4%	6%	4%	2%
Other Income	135	551	164	686	513	735
Depreciation and Amortisation Expense	269	267	255	536	507	1,013
Earning before Interest & Tax (EBIT)	**(37)**	**883**	**88**	**846**	**313**	**68**
EBIT Margin	(1%)	15%	2%	8%	4%	0%
Finance costs	37	33	24	70	48	95
Profit/(Loss) before exceptional items	**(74)**	**850**	**64**	**776**	**265**	**(27)**
PBT Margin	(1%)	15%	1%	7%	3%	0%
One time Impact of New Labour Code	-	-	-	-	-	(20)
Profit/(Loss) after exceptional items before tax	**(74)**	**850**	**64**	**776**	**265**	**(47)**
Current tax	11	43	-	54	-	-
Income tax adjustment of earlier years	(4)	3	-	(1)	-	(5)
Deferred Tax	(46)	195	98	149	80	12
Profit/(Loss) for the period	**(35)**	**609**	**(34)**	**574**	**185**	**(54)**
Net Profit/(Loss) Margin after tax	(1%)	11%	(1%)	5%	2%	0%
Other Comprehensive Income	-	(19)	(2)	(19)	(6)	(17)
Total Comprehensive income/(loss) for the period	**(35)**	**590**	**(36)**	**555**	**179**	**(71)**

DISCLAIMER

Dai-ichi Karkaria Limited may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Dai-ichi Karkaria Limited. All information contained in this presentation may be forward-looking statements that involve risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements publicly, whether as a result of new information, future events, or otherwise. Actual results, performances or achievements could differ materially from those expressed or implied in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This presentation should be read in conjunction with the financial statements issued from time to time.